This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Viewpoint: drug price protections create monopoly risk
The piece argues that after patent expiry generic competition should lower prices but a closed distribution system and regulatory hurdles keep rivals out. It cites Daraprim’s 5000 percent price jump under Turing and notes 40 drugs shielded from competition. It urges FDA enforcement and possible penalties to restore affordable access.
MENTIONED IN THIS ARTICLE
Associated Press
Jama Dermatology
Martin Shkreli
Turing Pharmaceuticals
Shkreli
Turing
U.S. Food and Drug Administration
Daraprim
Generic Pharmaceutical Association
Pharmacy
FDA
U.S. House Oversight and Government Reform Committee